50% off Premium Yearly

NYSE:BDX
This summary was created by AI, based on 2 opinions in the last 12 months.
Becton Dickinson (BDX) is undergoing significant transformation as it recently spun off its life sciences business and merged with Waters Corporation (WAT), shifting focus towards becoming a pure-play medical technology company. This strategic move aims to enhance growth and profitability within higher-margin areas. However, analysts have revised earnings projections downward, forecasting $12.50 EPS for 2026 compared to the previous estimate of $15. While operating margin expectations have risen to 25%, the inherent risks associated with such structural changes warrant a cautious approach. Despite a relatively inexpensive valuation at 14x, expert opinions reflect a wait-and-see attitude, with one analyst expressing reluctance to invest in turnaround scenarios, preferring investments with more certain outcomes. The anticipated price target remains optimistic at $200.
(A Top Pick Aug 29/18, Up 18%) They do healthcare--hospitals, clinics--as an end-to-end service provider. They give hospital admin the software and provide all the products you'd need, like catheters or surgical equipment. Really they have no competition. Their customers stay loyal. They made a recent acquisition that gives them more international exposure. It doesn't have as much regulatory risk as other healthcare or pharma companies.
It was a top pick for him in the past recently acquired CR Bald. A one stop shop for hospitals and clinics for all one time use medical devices (needles, etc.). Full service company from sales to programming to reordering, etc. now a gigantic company. Very good earnings. Very good guidance. They are going to benefit from tax reform. Big tail winds in healthcare. The biggest risk in healthcare is what Amazon is going to do. But not a lot of competition on the space. Just the US government spends 1.3 trillion dollars a year in health care.